Byungwoo Ryu, Ph.D.
Assistant Professor of Dermatology
Boston University School of Medicine
Boston University School of Medicine, Department of Dermatology
609 Albany Street, Boston, MA 02118
|1990||BS/MS||Chemistry, Chonbuk National University, Chonju, Korea|
|1997||PhD||Molecular Toxicology, Oregon State University, Corvallis, OR|
|1999||Postdoctoral Fellow||Receptor Biology and Gene Expression, National Cancer Institute,Bethesda, MD|
|2003||Postdoctoral Fellow||Oncology, Johns Hopkins University School of Medicine, Baltimore, MD|
Melanoma, Epigenetic cancer therapy, Chromatin structure and gene regulation, Epigenetic modulation of cancer-associated signaling pathways
Epigenetic therapy is the use of epigenome-editing techniques or drugs to treat human diseases, including cancer. Despite many challenges in clinical applications of such epigenetic therapy, significant advances have been made in exploring and identifying underlying epigenetic mechanisms and potential molecular targets for cancer therapy. We are particularly interested in studying chromatin remodeling enzymes, such as histone and DNA modifiers as potential targets for cancer and overcoming targeted-therapy resistance. We use chemical and genetics approaches (small molecule inhibitors and CRISPR technology for gene knockout) to investigate therapeutic potentials of such epigenetic targets including animal models and system biological tools. Melanoma is a model cancer type we employ for our study. These projects in our lab are supported by NIH. Postdoctoral research opportunities are currently available. Interested candidates are encouraged to contact Dr. Ryu at email@example.com
- Kalin JH, Wu M, Gomez AV, Song Y, Das J, Hayward D, Adejola N, Wu M, Panova I, Chung HJ, Kim E, Roberts HJ, Roberts JM, Prusevich P, Jeliazkov JR, Roy Burman SS, Fairall L, Milano C, Eroglu A, Proby CM, Dinkova-Kostova AT, Hancock WW, Gray JJ, Bradner JE, Valente S, Mai A, Anders NM, Rudek MA, Hu Y, Ryu B, Schwabe JWR, Mattevi A, Alani RM, Cole PA. CoREST in Peace: Dual Action Inhibitors of Histone Deacetylase and Demethylase. Nature (submitted)
- Kim E, Zucconi BE, Meyers DJ, McGee J, Venkatesh S, Cohen DL, Gonzalez EC, Cole PA, Ryu B, Alani RM. The p300-MITF Axis is a Critical Therapeutic target in Human Melanoma. Cancer Cell (submitted)
- Eisenstein A, Panova I, Chung HJ, Goldberg LJ, Zhang Q, Lazova R, Bhawan J, Busam KJ, Symanowski JT, Alani RM, Ryu B. Quantitative assessment of Neuropilin-2 as a Simple and Sensitive Diagnostic Assay for Spitzoid Melanocytic Legions. Melanoma Res. (submitted)
- Hwang S, Kim HE, Min M, Raghunathan R, Panova IP, Munshi R, Ryu B. Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma. J Invest Dermatol. 2015 Sep; 135(9):2283-91.
- Rossi M, Tuck J, Kim OJ, Panova I, Symanowski JT, Mahalingam M, Riker AI, Alani RM, Ryu B. Neuropilin-2 Gene Expression Correlates with Malignant Progression in Cutaneous Melanoma. Br J Dermatol. 2013 Dec 20. Doi: 10.111/bjd.12801. [Epub ahead of print]
- Cao J, Wan L, Hacker E, Dai X, Lenna S, Jimenez-Cervantes C, Wang Y, Leslie NR, Xu GX, Widlund HR, Ryu B, Alani RM, Dutton-Regester K, Goding CR, Hayward NK, Wei W, Cui R. MC1R Is a Potent Regulator of PTEN after UV Exposure in Melanocytes. Mol Cell. 2013 Aug 22; 51(4):409-22.
- Ryu B, Moriarty WF, Stine MJ, Deluca A, Kim DS, Meeker AK, Grills LD, Switzer RA, Eller MS, Alani RM. Global Analysis of BRAF(V600E) Target Genes in Human Melanocytes Identifies Matrix Metalloproteinase-1 as a Critical Mediator of Melanoma Growth. J Invest Dermatol. 2011 Jul; 131(7):1579-83.